Start-up funding will aid in the establishment and growth of the network’s operations.
The American Thrombosis and Hemostasis Network (ATHN) received start-up funding from Novo Nordisk. The significant, unrestricted grant over five years will help it establish and grow organizational leadership and operational infrastructure, according to ATHN.
Founded in July 2006, ATHN manages a secure national database that will support clinical outcome analysis, research, advocacy, and public health reporting in the thrombosis and hemostasis community.
“This unrestricted grant will allow us to truly begin defining and standardizing a secure, national database and the processes surrounding it to benefit patients and providers throughout our community,” says Diane Aschman, president and CEO of ATHN.
In a joint effort with the CDC Division of Blood Disorders, ATHN says it will create a coalition with the 140 federally funded hemophilia treatment centers. It believes that this will conserve resources through the use of a common information infrastructure, so data will no longer be at risk for loss or fragmentation.
The ATHN states that Novo Nordisk will not receive preferential access to the database developed nor the services provided. An open and transparent process for requesting access to data will be established via ATHN’s Privacy and Data Security Committee currently in the formative stage.